Nanoformulation and characterization of Nomilin (cas 1063-77-0) with different poly (lactic-co-glycolic acid) resomers and surfactants for the enhanced inhibition of α-amylase and angiotensin-converting-enzyme

Add time:07/28/2019    Source:sciencedirect.com

To overcome the solubility and bioavailability challenges of Nomilin (cas 1063-77-0), we have formulated and characterized a nanoparticle-based delivery system. Nomilin nanoparticles were prepared with poly (lactic-co-glycolic acid) (PLGA) resomers of different co-polymer composition and molecular weights with two surfactant, didodecyl dimethyl ammonium bromide (DMAB) and pluronic F-68 (PF-68) at three nomilin loading levels (30%, 40% and 50%) through modified emulsion diffusion evaporation technique. The smallest mean particle sizes, 135–188 nm, were obtained with DMAB as the surfactant. The PLGA (50:50) polymer exhibited a slow release pattern in all loading levels, except 40% loading with PF-68. Significantly higher in vitro inhibition of α-amylase and angiotensin-converting enzyme activity was observed with nomilin-loaded PLGA nanoparticles as compared to pure nomilin. Thus, nomilin nanoparticles can be explored for understanding the various biological properties using in vivo studies.

We also recommend Trading Suppliers and Manufacturers of Nomilin (cas 1063-77-0). Pls Click Website Link as below: cas 1063-77-0 suppliers

Prev:Citrus limonoid Nomilin (cas 1063-77-0) inhibits osteoclastogenesis in vitro by suppression of NFATc1 and MAPK signaling pathways
Next:Lithium benzoate doped high performance n-type diketopyrrolopyrrole based organic thin-film transistors)